低剂量阿糖胞苷联合tosedostat对比单用低剂量阿糖胞苷治疗不适合强化疗的老年急性髓系白血病:LI-1随机试验结果
LI-1随机试验纳入243例不适合强化疗的初治老年AML患者,1:1随机接受低剂量阿糖胞苷联合tosedostat或单用低剂量阿糖胞苷。
要点
- 探索性分析未发现从tosedostat获益的亚组。
核心结论
- 在不适合强化疗的初治老年AML患者中,低剂量阿糖胞苷联合tosedostat未产生生存获益。
研究设计与样本
- LI-1试验中的随机研究,243例不适合强化疗的初治老年AML患者按1:1随机接受低剂量阿糖胞苷联合tosedostat或单用低剂量阿糖胞苷。
主要发现
- 探索性分析未发现任何亚组从tosedostat获益。
临床怎么用
- 对于不适合强化疗的老年AML患者,不推荐在低剂量阿糖胞苷基础上常规联合tosedostat。
局限性
- 探索性分析未发现获益亚组,但研究未报告其他局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Older patients with acute myeloid leukaemia (AML) account for nearly half of those with the disease. Because they are perceived to be unfit for, unwilling to receive, or unlikely to benefit from conventional chemotherapy they represent an important unmet need. Tosedostat is a selective oral aminopeptidase inhibitor, which in phase I/II trials showed acceptable toxicity and encouraging efficacy. We report the only randomised study of low-dose cytosine arabinoside (LDAC) combined with tosedostat (LDAC-T) versus LDAC in untreated older patients not suitable for intensive treatment. A total of 243 patients were randomised 1:1 as part of the 'Pick-a-Winner' LI-1 trial. There was a statistically non-significant increase in the complete remission (CR) rate with the addition of tosedostat, LDAC-T 19% versus LDAC 12% [odds ratio (OR) 0·61, 95% confidence interval (CI) 0·30-1·23; P = 0·17]. For overall response (CR+CR with incomplete recovery of counts), there was little evidence of a benefit to the addition of tosedostat (25% vs. 18%; OR 0·68, 95% CI 0·37-1·27; P = 0·22). However, overall survival (OS) showed no difference (2-year OS 16% vs. 12%, hazard ratio 0·97, 95% CI 0·73-1·28; P = 0·8). Exploratory analyses failed to identify any subgroup benefitting from tosedostat. Despite promising pre-clinical, early non-randomised clinical data with acceptable toxicity and an improvement in response, we did not find evidence that the addition of tosedostat to LDAC produced a survival benefit in this group of patients with AML. International Standard Randomised Controlled Trial Number: ISRCTN40571019.
引用
- Dennis M, Burnett A, Hills R, et al. A randomised evaluation of low-dose cytosine arabinoside (ara-C) plus tosedostat versus low-dose ara-C in older patients with acute myeloid leukaemia: results of the LI-1 trial. Br J Haematol. 2021. PMID: 33961292. doi:10.1111/bjh.17501
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。